Document is current
Any future updates will be listed below
-
Authors
Stuut, A. H. G.
Nijssen, C.
van der Wagen, L.
van Rhenen, A.
Daenen, L. G. M. https://orcid.org/0000-0001-9835-3223
Janssen, A.
Verheij, F. A.
Brinkman, I.
Verduyn Lunel, F. M.
Koene, H.
Fijnheer, R.
Prins, H. J.
Westinga, K.
Drylewicz, J. https://orcid.org/0000-0002-9434-8459
Kuball, J. https://orcid.org/0000-0002-3914-7806
de Witte, M. A. https://orcid.org/0000-0001-7470-2994
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (13493)
- License Information
-
More Information
Article History
Received: 28 August 2024
Revised: 8 January 2025
Accepted: 14 February 2025
First Online: 15 March 2025
Competing interests
: JK is the inventor of multiple patents dealing with gdTCRs, ligands, and isolation strategies of engineered immune cells. JK is cofounder and shareholder of Gadeta (). JK received research, advisor, and clinical study support from Miltenyi Biotech. JK received further research support from Novartis and Gadeta.
